Skip to main navigation
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • Vudalimab (PD-1 x CTLA-4)
    • XmAb819 (ENPP3 x CD3)
    • XmAb808 (B7-H3 x CD28)
    • XmAb541 (CLDN6 x CD3)
    • Plamotamab (CD20 x CD3)
    • XmAb942 (Xtend TL1A)
    • XmAb657 (CD19 x CD3)
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Corporate Responsibility
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • Careers
    • Opportunities

You are here:
Home / Investors /

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Corporate Responsibility
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

Email Alert Registration

If you have already signed up for Xencor, Inc. Email Alerts, please enter your email address in the field below and submit.

Unsubscribe from all Xencor, Inc. email alerts

Xencor © Copyright 2024 | Privacy Policy
Scroll to top